Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2025-10-01
DOI
https://doi.org/10.1002/jha2.70169
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models

Mayu Tomita, Sei Shu, Natsumi Kawasaki, Shigeki Yoshiura et al.
eJHaem
CAR-T cell therapy research
article

Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models

Mayu Tomita, Sei Shu, Natsumi Kawasaki, Shigeki Yoshiura, Yoriko Yamashita‐Kashima, Xiaoxiao Liu
article en

Abstract

No abstract available for this paper.
eJHaemVol. 6(5)
Chugai Pharma (United States) (US)
F. Hoffmann-La Roche, Chugai Pharmaceutical
Openalex Percentile: Top 59%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.